Skip to content

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

A single-center, open-label, randomized, three-way, crossover trial to evaluate the bioavailability of brexpiprazole (OPC-34712) orally disintegrating tablets relative to brexpiprazole (OPC-34712) conventional tablets in healthy male subjects

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080223296
Enrollment
16
Registered
2016-08-18
Start date
2016-09-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult male

Interventions

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Capable of providing written informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all requirements of the trial

Exclusion criteria

Exclusion criteria: - Clinically significant abnormality at the time of screening (eg, significant deviation from reference ranges) or in medical history that, in the opinion of investigator or sponsor may place the subject at risk or interfere with outcome variables, including drug absorption, distribution, metabolism, and excretion - History of serious mental disorder - History of drug or alcohol abuse within 2 years prior to screening - History of any significant drug allergy - Use of an investigational drug within 120 days prior to the first dosing of trial drug - Use of tobacco products or daily exposure to secondhand smoke within 2 months prior to screening - Consumption of grapefruit, grapefruit products, Seville oranges, Seville orange products, starfruit, or starfruit products within 72 hours prior to dosing - Use of prescription, over-the-counter, or herbal medication, vitamin supplements, or St. John's Wort within 14 days prior to the first dosing of trial drug, or of antibiotics within 30 days prior to the first dosing of trial drug - History of major surgery of the digestive tract (excluding appendectomy) - Any subject who, in the opinion of the investigator, should not participate in the trial

Design outcomes

Primary

MeasureTime frame
bioequivalence Cmax, AUC, Bioavailability

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026